Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A T lymphoblastic lymphoma that occurs during childhood.
Biomarker and diagnostic research for T-cell childhood lymphoblastic lymphoma has been reported in the published literature.
12 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 2 PHASE2, 5 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06136364](https://clinicaltrials.gov/study/NCT06136364) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:02 PM UTC
Common questions about T-cell childhood lymphoblastic lymphoma
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study |
PHASE1 |
Hebei Senlang Biotechnology Inc., Ltd. |
RECRUITING |
[NCT07523555](https://clinicaltrials.gov/study/NCT07523555) | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | PHASE1 | Beijing Biotech | RECRUITING |
[NCT06376721](https://clinicaltrials.gov/study/NCT06376721) | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | PHASE1 | Beijing Tongren Hospital | RECRUITING |
200 publications have been identified in PubMed for T-cell childhood lymphoblastic lymphoma. Research spans Review / Meta-Analysis (21%), Basic Science / Preclinical (18%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 42 | 21% |
Laboratory research | 36 | 18% |
Patient case studies | 33 | 17% |
Disease patterns and progression | 33 | 17% |
Clinical study results | 22 | 11% |
Testing and diagnosis research | 13 | 7% |
New treatment approaches | 12 | 6% |
Other research | 9 | 5% |
Zhao M (2026). [PMID: 41959896](https://pubmed.ncbi.nlm.nih.gov/41959896/). *Front Oncol*. [Epidemiology / Natural History]
Karanam Y (2026). [PMID: 41060554](https://pubmed.ncbi.nlm.nih.gov/41060554/). *Indian pediatrics*. [Epidemiology / Natural History]
Hazar V (2026). [PMID: 41400973](https://pubmed.ncbi.nlm.nih.gov/41400973/). *Leukemia & lymphoma*. [Epidemiology / Natural History]
Albuquerque TM (2026). [PMID: 41846574](https://pubmed.ncbi.nlm.nih.gov/41846574/). *European journal of haematology*. [Case Report / Case Series]
Bosch-Schips J (2026). [PMID: 41611915](https://pubmed.ncbi.nlm.nih.gov/41611915/). *Pathologie (Heidelb)*. [Review / Meta-Analysis]
Hamidi R (2026). [PMID: 41747190](https://pubmed.ncbi.nlm.nih.gov/41747190/). *Blood Adv*. [Review / Meta-Analysis]
Østergaard A (2026). [PMID: 40587953](https://pubmed.ncbi.nlm.nih.gov/40587953/). *Acta Haematol*. [Review / Meta-Analysis]
Balduzzi A (2026). [PMID: 40820816](https://pubmed.ncbi.nlm.nih.gov/40820816/). *Haematologica*. [Clinical Trial Publication]
Shen X (2026). [PMID: 42141436](https://pubmed.ncbi.nlm.nih.gov/42141436/). *J Cardiothorac Surg*. [Clinical Trial Publication]
Ströbel P (2026). [PMID: 41537898](https://pubmed.ncbi.nlm.nih.gov/41537898/). *Pathologie (Heidelb)*. [Review / Meta-Analysis]
AI-curated news mentioning T-cell childhood lymphoblastic lymphoma
Updated Mar 8, 2026
A case study highlights advanced lymphoblastic lymphoma in the leukaemic phase, which resulted in sudden and fatal CNS hemorrhage. This underscores the critical need for awareness and research into the aggressive nature of this lymphoma variant.